JPWO2021202675A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2021202675A5 JPWO2021202675A5 JP2022560205A JP2022560205A JPWO2021202675A5 JP WO2021202675 A5 JPWO2021202675 A5 JP WO2021202675A5 JP 2022560205 A JP2022560205 A JP 2022560205A JP 2022560205 A JP2022560205 A JP 2022560205A JP WO2021202675 A5 JPWO2021202675 A5 JP WO2021202675A5
- Authority
- JP
- Japan
- Prior art keywords
- cytokine
- masked
- linker
- seq
- life prolonging
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063003824P | 2020-04-01 | 2020-04-01 | |
| US63/003,824 | 2020-04-01 | ||
| US202063118571P | 2020-11-25 | 2020-11-25 | |
| US63/118,571 | 2020-11-25 | ||
| PCT/US2021/025103 WO2021202675A1 (en) | 2020-04-01 | 2021-03-31 | Masked il-2 cytokines and their cleavage products |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2023520517A JP2023520517A (ja) | 2023-05-17 |
| JPWO2021202675A5 true JPWO2021202675A5 (https=) | 2024-04-10 |
| JP2023520517A5 JP2023520517A5 (https=) | 2024-04-10 |
| JP7735306B2 JP7735306B2 (ja) | 2025-09-08 |
Family
ID=77928454
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022560205A Active JP7735306B2 (ja) | 2020-04-01 | 2021-03-31 | マスクされたｉｌ－２サイトカイン及びその切断産物 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20230151072A1 (https=) |
| EP (1) | EP4126247A4 (https=) |
| JP (1) | JP7735306B2 (https=) |
| KR (1) | KR20220161404A (https=) |
| CN (1) | CN115942976A (https=) |
| AU (1) | AU2021245922A1 (https=) |
| BR (1) | BR112022019689A2 (https=) |
| CA (1) | CA3172649A1 (https=) |
| IL (1) | IL296915A (https=) |
| MX (1) | MX2022012311A (https=) |
| PH (1) | PH12022552627A1 (https=) |
| TW (1) | TW202204388A (https=) |
| WO (1) | WO2021202675A1 (https=) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2019271148B9 (en) | 2018-05-14 | 2025-05-29 | Werewolf Therapeutics, Inc. | Activatable interleukin-2 polypeptides and methods of use thereof |
| CA3100005A1 (en) | 2018-05-14 | 2019-11-21 | Werewolf Therapeutics, Inc. | Activatable cytokine polypeptides and methods of use thereof |
| CN120463822A (zh) | 2018-09-27 | 2025-08-12 | 西里欧发展公司 | 掩蔽型细胞因子多肽 |
| KR20220023988A (ko) | 2019-05-14 | 2022-03-03 | 웨어울프 세라퓨틱스, 인크. | 분리 모이어티 및 이의 사용 방법 |
| BR112022009110A2 (pt) | 2019-11-14 | 2022-07-26 | Werewolf Therapeutics Inc | Polipeptídeos de citocina ativáveis e métodos de uso destes |
| AU2021254283B2 (en) * | 2020-04-10 | 2025-12-11 | Cytomx Therapeutics, Inc. | Activatable cytokine constructs and related compositions and methods |
| WO2022115865A2 (en) * | 2020-11-25 | 2022-06-02 | Xilio Development, Inc. | Tumor-specific cleavable linkers |
| JP2024511387A (ja) | 2021-03-16 | 2024-03-13 | シートムエックス セラピューティクス，インコーポレイテッド | マスクした活性化可能サイトカイン構成体ならびに関連する組成物及び方法 |
| WO2023161853A1 (en) | 2022-02-23 | 2023-08-31 | Bright Peak Therapeutics Ag | Activatable il-18 polypeptides |
| MX2024010488A (es) * | 2022-02-28 | 2024-09-05 | Xilio Dev Inc | Citocinas dirigidas y metodos de uso de estas. |
| WO2023164286A1 (en) * | 2022-02-28 | 2023-08-31 | Xilio Development, Inc. | Engineered cd122 compositions and methods thereof |
| KR20250039361A (ko) * | 2022-07-15 | 2025-03-20 | 실리오 디벨럽먼트, 인크. | 담체로서의 조작된 절단성 Fc 도메인 및 이의 사용 방법 |
| CN117917438A (zh) * | 2022-10-21 | 2024-04-23 | 北京诺诚健华医药科技有限公司 | 抗体融合蛋白及其制备和应用 |
| WO2024150175A1 (en) | 2023-01-11 | 2024-07-18 | Bright Peak Therapeutics Ag | Conditionally activated proteins and methods of use |
| US20240417436A1 (en) | 2023-01-11 | 2024-12-19 | Bright Peak Therapeutics Ag | Conditionally activated immunocytokines and methods of use |
| TW202517789A (zh) * | 2023-07-04 | 2025-05-01 | 香港商禮邦醫藥（香港）有限公司 | Ｋｌｋ１融合蛋白質的製備方法 |
| WO2025041101A1 (en) | 2023-08-23 | 2025-02-27 | Bright Peak Therapeutics Ag | Activatable il-18 immunocytokines and uses thereof |
| WO2025049948A1 (en) * | 2023-08-30 | 2025-03-06 | Xilio Development, Inc. | Masked il-2 cytokines and methods of use thereof |
| WO2025162454A1 (zh) * | 2024-02-02 | 2025-08-07 | 北京昌平实验室 | 双特异性抗体和细胞因子融合蛋白及其应用 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SK782002A3 (en) * | 1999-07-21 | 2003-08-05 | Lexigen Pharm Corp | FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens |
| EP2553101A4 (en) * | 2010-04-02 | 2013-09-04 | Univ Rochester | PROTEASE-ACTIVATED CYTOKINES |
| HUE029139T2 (hu) * | 2011-02-10 | 2017-02-28 | Roche Glycart Ag | Mutáns interleukin-2 polipeptidek |
| EP2882775B1 (en) * | 2012-08-09 | 2018-02-14 | Roche Glycart AG | Asgpr antibodies and uses thereof |
| US9605084B2 (en) * | 2013-03-15 | 2017-03-28 | Xencor, Inc. | Heterodimeric proteins |
| CN108218993B (zh) * | 2018-01-05 | 2020-11-17 | 阿思科力(苏州)生物科技有限公司 | 一种以robo1为靶点的双特异性抗体及其制备和应用 |
| WO2019173832A2 (en) * | 2018-03-09 | 2019-09-12 | AskGene Pharma, Inc. | Novel cytokine prodrugs |
| AU2019271148B9 (en) * | 2018-05-14 | 2025-05-29 | Werewolf Therapeutics, Inc. | Activatable interleukin-2 polypeptides and methods of use thereof |
| US12459980B2 (en) * | 2018-07-25 | 2025-11-04 | AskGene Pharma, Inc. | IL-21 prodrugs and methods of use thereof |
| CN112867503A (zh) * | 2018-08-24 | 2021-05-28 | 希望之城 | 掩蔽的细胞因子缀合物 |
| CN120463822A (zh) * | 2018-09-27 | 2025-08-12 | 西里欧发展公司 | 掩蔽型细胞因子多肽 |
| JP2022533254A (ja) | 2019-05-24 | 2022-07-21 | プロヴィヴァ セラピューティクス （ホン コン） リミテッド | Ｉｌ－２組成物およびその使用方法 |
-
2021
- 2021-03-31 JP JP2022560205A patent/JP7735306B2/ja active Active
- 2021-03-31 CN CN202180039119.8A patent/CN115942976A/zh active Pending
- 2021-03-31 TW TW110112016A patent/TW202204388A/zh unknown
- 2021-03-31 BR BR112022019689A patent/BR112022019689A2/pt unknown
- 2021-03-31 KR KR1020227037408A patent/KR20220161404A/ko active Pending
- 2021-03-31 PH PH1/2022/552627A patent/PH12022552627A1/en unknown
- 2021-03-31 EP EP21780178.6A patent/EP4126247A4/en active Pending
- 2021-03-31 MX MX2022012311A patent/MX2022012311A/es unknown
- 2021-03-31 AU AU2021245922A patent/AU2021245922A1/en active Pending
- 2021-03-31 CA CA3172649A patent/CA3172649A1/en active Pending
- 2021-03-31 WO PCT/US2021/025103 patent/WO2021202675A1/en not_active Ceased
- 2021-03-31 IL IL296915A patent/IL296915A/en unknown
- 2021-03-31 US US17/995,163 patent/US20230151072A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPWO2021202675A5 (https=) | ||
| JP2025032113A5 (https=) | ||
| JP2020508691A5 (https=) | ||
| JPWO2021189139A5 (https=) | ||
| JP2021521822A5 (https=) | ||
| Mohler et al. | Soluble tumor necrosis factor (TNF) receptors are effective therapeutic agents in lethal endotoxemia and function simultaneously as both TNF carriers and TNF antagonists. | |
| ES2327819T3 (es) | Imidazolidinonas como inhibidores de la serina proteasa ns3 del virus de la hepatitis c. | |
| JPWO2021119516A5 (https=) | ||
| JP4255618B2 (ja) | 単鎖二官能性糖タンパク質ホルモン | |
| RU2011138951A (ru) | Пропротеины и способы их применения | |
| JP2012520059A5 (https=) | ||
| JP2021523741A5 (https=) | ||
| JP2021531265A5 (https=) | ||
| JPWO2021097376A5 (https=) | ||
| JP2004508828A (ja) | 標的−特異的プロドラッグとしての使用のための抗体サイトカイン−サイトカインインヒビター（セレクトカイン）からの融合タンパク質 | |
| JPWO2019222296A5 (https=) | ||
| EP4019536A1 (en) | Immunocytokine, preparation for same, and uses thereof | |
| ES2241040T3 (es) | Proteinas hibridas que forman heterodimeros. | |
| JPWO2019209965A5 (https=) | ||
| JPWO2020012485A5 (https=) | ||
| KR100249576B1 (ko) | 프로드럭 활성화를 위한 융합 단백질, 이의 제조방법 및 용도 | |
| JPWO2020011972A5 (https=) | ||
| JPWO2022115865A5 (https=) | ||
| JP2636864B2 (ja) | 免疫グロブリンｅに対するポリペプチド競争体 | |
| JPH04505019A (ja) | ガンマインターフェロンのポリペプチド性阻害剤 |